SICTEC
Single Cell Technologies for SMEs
| Coordinatore | BIOFLUIDIX GMBH
Organization address
address: GEORGE KOEHLER ALLEE 103 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 1˙400˙224 € |
| EC contributo | 1˙039˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2013 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
BIOFLUIDIX GMBH
Organization address
address: GEORGE KOEHLER ALLEE 103 contact info |
DE (FREIBURG IM BREISGAU) | coordinator | 238˙000.00 |
| 2 |
Primadiag SAS
Organization address
address: Avenue Gaston Roussel 102 contact info |
FR (ROMAINVILLE) | participant | 315˙000.00 |
| 3 |
BIOSPARQ BV
Organization address
address: GALILEIWEG 8 contact info |
NL (LEIDEN) | participant | 273˙750.00 |
| 4 |
SOPHION BIOSCIENCE A/S
Organization address
address: Baltorpvej 154 contact info |
DK (Ballerup) | participant | 107˙250.00 |
| 5 |
Innovative Technologies in Biological Systems
Organization address
city: Derio contact info |
ES (Derio) | participant | 93˙000.00 |
| 6 |
ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Organization address
address: FAHNENBERGPLATZ contact info |
DE (FREIBURG) | participant | 6˙000.00 |
| 7 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 6˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project is focused on development of technologies for separation and manipulation of single biological cells for life science research and medical applications. The research plan is built upon the results of the FP7 project PASCA (GA 257073, started 01.09.2010). The single cell manipulation technology (SCM technology) developed there is based on inkjet-like printing of single biological cells confined in free flying micro droplets. It constitutes a universal platform for single cell analysis that has been proven to have high potential for many life science applications. The objective of this project is to support the participating SMEs and companies to take up the SCM technology, to realize their own applications and to develop them into innovative products for the medical, biomedical and pharmaceutical markets. Central element of the research is the SCM prototype instrument as presented in numerous publications (see www.pasca.eu). The actual project will provide validation and extension of the use of this prototype instrument and deal with necessary improvements and modifications of pre-production prototypes towards the specific needs and applications of the SME partners. In particular also topics affecting commercial exploitation like e.g. application development, design for manufacturability, reliability issues, cost and throughput optimization, extension of technical specifications, and preparation of CE IVD labeling will be investigated. Applications targeted by the individual SMEs are considering fast pathogen detection for clinical use by combining the SCM technology with MALDI TOF mass spectroscopy of single bacteria, instruments for single cell cancer and stem cell research, methods for monoclonal cell line development and in-vitro medical diagnostic applications. The anticipated innovations stemming from this research will be exploited by the involved SMEs individually as well as jointly through several innovative products targeted for different markets and applications.'